Advertisements

Stocking Stuffers

 

Antibe Therapeutics Inc. (ATE:CA) Stock Quote

Detailed Quote for Antibe Therapeutics Inc. (ATE:CA)
$ 0.27 0.00 (0.00%) Volume: 241.66k 3:59 PM EDT 22-Mar-2019
Today 5d 1m 3m 1y more
Last Price
0.27
Change $
Change %
Tick
  
Bid
0.27
Bid Size
22,000
Ask
0.275
Ask Size
62,000
Open
0.275
High
0.275
Low
0.265
Prev Close
0.27
Last Trade
03/22/19
Volume
241.66k
52 Wk Hi
0.51999998
52 Wk Low
0.234999999
Market Cap
65.72m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
243,392,476
EPS (TTM)
-0.05
PE Ratio
N/A
Exchange
TSXV
News and Media for Antibe Therapeutics Inc. (ATE:CA)
Sector News | Topic News
News for Antibe Therapeutics Inc. (ATE:CA)
Wed, Feb 27, 2019
8:44 AM Antibe Therapeutics Inc. Announces Closing of $5.75 Million Bought Deal Offering - Business Wire Canada
8:44 AM Antibe Therapeutics Inc. Announces Closing of $5.75 Million Bought Deal Offering - Business Wire
Fri, Feb 22, 2019
7:00 AM Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company - Business Wire
7:00 AM Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company - Business Wire Canada
Fri, Feb 15, 2019
7:30 PM Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results - Business Wire
7:30 PM Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results - Business Wire Canada
Mon, Feb 04, 2019
4:16 PM IIROC Trading Resumption - ATE - Canada Newswire
4:01 PM Antibe Therapeutics Announces $5 Million Bought Deal Offering - Business Wire
4:01 PM IIROC Trading Halt - ATE - Canada Newswire
Mon, Jan 21, 2019
7:00 AM Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346 - Business Wire
Wed, Dec 19, 2018
7:00 AM Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises - Business Wire
Fri, Nov 30, 2018
7:00 AM Antibe Therapeutics to Present at the 11th Annual LD Micro Main Event on December 4, 2018 - Business Wire
Tue, Nov 27, 2018
7:00 AM Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346 - Business Wire
Fri, Nov 23, 2018
6:00 PM Antibe Therapeutics Reports Q2 2019 Interim Financial and Operating Results - Business Wire
Mon, Oct 22, 2018
7:00 AM Antibe Therapeutics Establishes Business Development Advisory Board - Business Wire
Wed, Oct 10, 2018
7:00 AM Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346 - Business Wire
Wed, Oct 03, 2018
5:00 PM Antibe Therapeutics Announces Grant of Restricted Share Units - Business Wire
Wed, Sep 05, 2018
7:00 AM Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea - Business Wire
Wed, Aug 29, 2018
6:45 PM Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results - Business Wire
7:30 AM Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346 - Business Wire
More News for ATE:CA >>

Tags for Antibe Therapeutics Inc.

Research stocks or mutual funds related to Antibe Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to ATE:CA. The keywords below have been associated to ATE:CA by either user submission or electronic means.